Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)

Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis: A Prospective Clinical, Immunopathologic and Molecular Analysis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02656134

Enrollment

Registered

2016-01-14

Start date

2015-03-31

Completion date

2016-12-31

Last updated

2016-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Adenomatous Polyposis

Keywords

Familial Adenomatous Polyposis

Brief summary

Background and study aim The relative risks of duodenal adenocarcinoma and ampullary carcinoma in Familial Adenomatous Polyposis (FAP) have been estimated 100 to 330 times higher than in general population. However risk factors, including a genotype-phenotype association for duodenal cancer in FAP has not been fully understood. The aim of this study is to determine risk factors associated with the development of advanced duodenal polyposis and ampullary adenomas in colectomized patients with FAP.

Interventions

PROCEDUREDuodenoscopy and enteroscopy

All patients will undergo duodenoscopy and classified according to Spigelman. Patients classified as Spigelman III and IV will undergo enteroscopy.

GENETICMolecular analysis.

DNA analysis

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patients with Familial Adenomatous Polyposis with colectomy, or scheduled for surgery.

Exclusion criteria

* Pregnancy, lactation

Design outcomes

Primary

Measure	Time frame
Genetic profile in FAP patients	one year

Countries

Brazil

Contacts

Primary ContactMarianny Sulbaran, MD

mariannysulbaran@gmail.com5511 948526841

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026